On January 23, 2026, Abbott’s Chairman and CEO, Robert Ford, acquired an additional 18,800 common shares, raising his total stake to 216,203 shares. This move underscores his conviction in the company’s long-term growth trajectory, coming at a time when the stock has experienced a modest pullback. Insider purchases at this level are relatively rare for the executive suite, signaling that management views current valuations as attractive and that recent operational headwinds are viewed as temporary.

During the most recent quarter, Abbott’s Nutrition segment faced margin pressure from elevated manufacturing costs, resulting in a mid-single-digit year-over-year sales decline and a temporary suppression of consumer demand. In contrast, the Medical Devices segment delivered robust double-digit revenue growth, led by its Continuous Glucose Monitoring franchise, which expanded unit shipments by over 20% year-over-year. Diagnostics revenue also showed resilience, with key immunoassay platforms posting low-double-digit gains, helping to mitigate Nutrition softness.

Abbott has reaffirmed its target of 7% sales growth and 10% EPS growth for fiscal 2025, driven by pipeline launches across diagnostics and devices, along with a normalization in nutritional volumes. Looking further ahead, management projects organic revenue growth of 6.5% to 7.5% in 2026, with adjusted earnings per share climbing at least 10%. Additionally, the planned acquisition of a leading molecular diagnostics company is expected to close in the second quarter of 2026, adding a new oncology screening vertical and bolstering Abbott’s long-term growth profile.